AtriCure Inc
NASDAQ:ATRC
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
19.86
42.53
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ATRC stock under the Base Case scenario is 51.52 USD. Compared to the current market price of 33.66 USD, AtriCure Inc is Undervalued by 35%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
AtriCure Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ATRC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
AtriCure Inc
Balance Sheet Decomposition
AtriCure Inc
Current Assets | 269.3m |
Cash & Short-Term Investments | 130.3m |
Receivables | 54.9m |
Other Current Assets | 84m |
Non-Current Assets | 345.8m |
PP&E | 49.6m |
Intangibles | 293.1m |
Other Non-Current Assets | 3m |
Current Liabilities | 74.4m |
Accounts Payable | 103.5m |
Accrued Liabilities | 41.5m |
Other Current Liabilities | -70.6m |
Non-Current Liabilities | 75.6m |
Long-Term Debt | 61.9m |
Other Non-Current Liabilities | 13.8m |
Earnings Waterfall
AtriCure Inc
Revenue
|
447.6m
USD
|
Cost of Revenue
|
-112.9m
USD
|
Gross Profit
|
334.7m
USD
|
Operating Expenses
|
-368.9m
USD
|
Operating Income
|
-34.2m
USD
|
Other Expenses
|
-4.8m
USD
|
Net Income
|
-38.9m
USD
|
Free Cash Flow Analysis
AtriCure Inc
USD | |
Free Cash Flow | USD |
ATRC Profitability Score
Profitability Due Diligence
AtriCure Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
AtriCure Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
ATRC Solvency Score
Solvency Due Diligence
AtriCure Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
AtriCure Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATRC Price Targets Summary
AtriCure Inc
According to Wall Street analysts, the average 1-year price target for ATRC is 41.95 USD with a low forecast of 26.26 USD and a high forecast of 63 USD.
Dividends
Current shareholder yield for ATRC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ATRC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 875 full-time employees. The company went IPO on 2005-08-05. The company develops, manufactures, and sells devices for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management include AtriClip System and LARIAT System.
Officers
The intrinsic value of one ATRC stock under the Base Case scenario is 51.52 USD.
Compared to the current market price of 33.66 USD, AtriCure Inc is Undervalued by 35%.